Browse > Article
http://dx.doi.org/10.4333/KPS.2010.40.1.015

Development of Pharmaceutical Dosage Form with New Sibutramine Salt  

Moon, Jin-Wook (College of Pharmacy, Chungnam National University)
Shin, Teak-Hwan (Chong Kun Dang Pharmaceutical Co.)
Lee, Dong-Wook (Chong Kun Dang Pharmaceutical Co.)
Cho, Jun-Young (Chong Kun Dang Pharmaceutical Co.)
Chang, Sung-Ju (Chong Kun Dang Pharmaceutical Co.)
Hwang, Sung-Joo (College of Pharmacy, Chungnam National University)
Publication Information
Journal of Pharmaceutical Investigation / v.40, no.1, 2010 , pp. 15-21 More about this Journal
Abstract
Sibutramine is an orally administered centrally-acting antiobesity agent and inhibits both noradrenaline(norephinephirine) and serotonin(5-HT) reuptake. These effects are contributed by its active metabolites, M1 and M2. However, as the free base form of sibutramine is an oil form in room temperature, it had the problem of handling and stability. Thus, this drug should be used in the form of acid salt form in the pharmaceutical application. Unfortunately, anhydrous sibutramine hydrochloride is highly hygroscopic and unstable. In order to solve the hygroscopicity of the anhydrous salt form, another sibutramine acid salt form must be developed as a hydrate form. In this study. to overcome these problems, various of sibutramine acid salt forms were prepared with the pharmaceutically available salts such as maleate, esylate, mandelate, camsylate, besylate, salicylate, tartrate, isethionate and malate forms, and their physicochemical properties were investigated. Sibutramine malate was selected for excellent solubility and stability among the listed salt forms above. Its pharmacokinetic parameters were evaluated in rats comparing with sibutramine HCl, resulting in similar parameters. In vitro dissolution study of sibutramine malate-loaded capsule was performed comparison with commercial product ($Reductil^{(R)}$) in pH 1.2, pH 4.0, pH 6.8 and water medium. Our results indicated that there were no significant differences in their dissolution profiles were similar in all tested medium. Thus, sibutramine malate-loaded capsule should be a potential candiate due to its excellent solubility, good stability and biosimilar absorption.
Keywords
sibutramine; acid salt; solubility; dissolution; pharmacokinetics; rat;
Citations & Related Records
연도 인용수 순위
  • Reference
1 한올제약, 용해도와 용출률이 향상된 시부트라민 함유 경구투여용 고체분산체, 대한민국특허청, 10-2006-0061063
2 S.C. Cheetham, J.A. Viggers, S.A. Butler, M.R. Prow and D.J. Heal, [$^3H$]Nisoxetine-A radioligand for noradrenaline reuptake sites: correlation with inhibition of [$^3H$]noradrenalineuptake and effect of DSP-4 lesioning and antidepressant treatments. Neuropharmacology, 35, 63-70 (1996).   DOI
3 I.P. Connoley, Y.L. Liu, I. Frost, I.P. Reckless, D.J. Heal and M.J. Stock, Thermogenic effects of sibutramine and its metabolites. Brit. J. Pharmacol., 126, 1487-1495 (1999).   DOI
4 I.P. Connoley, I. Frost, D.J. Heal and M.J. Stock, Role of beta-adrenoceptors in mediating the thermogenic effects of sibutramine, Brit. J. Pharmacol., 117, 170 (1996).   DOI   ScienceOn
5 Z. Abolfathi, J. Couture, F. Vallee, M. LeBel, M. Tanguay and E. Masson, A pilot study to evaluate the pharmacokinetics of sibutramine in healthy subjects under fasting and fed conditions. J. Pharm. Pharmaceut. Sci., 7(3), 345-349 (2004).
6 더 부츠 캄파니 피엘씨, 1-(1-아릴사이클로부틸)알킬아민 유도체의 제조방법, 대한민국특허청, 10-1982-0001506
7 더 부츠 캄파니 피엘씨, N,N-디메틸-1-(1-(4-클로로페닐)사이클로부틸)-3-메틸부틸아민 염산염 일수화물의 제조방법, 대한민국특허청, 10-1986-0010764
8 H.C. Jackson, A.M. Needham, L.J. Hutchins, S.E. Mazurkiewicz and D.J. Heal, Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat, Br. J. Pharmacol., 121, 1758–1762 (1997b).   DOI
9 H.C. Jackson, M.C. Bearham, L.J. Hutchins, S.E. Mazurkiewicz, A.M. Needham and D.J. Heal, Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat, Br. J. Pharmacol., 121, 1613-1618 (1997a).   DOI
10 S.C. Cheetham, C.J. Kettle, K.F. Martin and D.J. Heal, $D_1$ receptor binding in rat striatum: modification by various $D_1$ and $D_2$ antagonists, but not by sibutramine hydrochloride, antidepressants or treatments which enhance central dopaminergic function, J. Neural Transm., 102, 35-46 (1995).   DOI
11 M.J. Stock, Sibutramine: a review of the pharmacology of a novel anti obesity agent, Int. J. Obes., 21 (Suppl. 1), S25-S29 (1997).
12 유한양행, 시부트라민을 함유하는 약제학적 조성물, 대한민국 특허청, 10-2005-0080825
13 한미약품, 시부트라민 메탄술폰산염의 결정성 반수화물을 포함하는 약학조성물, 대한민국특허청, 10-2003-0053752
14 W.R. Buckett, P.C. Thomas and G.P. Luscombe, The pharmacology of sibutramine hydrochloride (BTS 54 524) a new antidepressant which induces rapid noradrenergic downregulation, Prog. Neuropsychopharmacol. Biol. Psychiatry.,12(5), 575-584 (1988).   DOI
15 M. Weintraub, A. Rubio, A. Golik, L. Byrne and M.L. Scheinbaum, Sibutramine in weight control: a dose-ranging efficacy study, Clin. Pharmacol. Ther., 50(3), 330-337 (1991).   DOI
16 G.P. Luscombe, N.A. Slater, M.B. Lyons, R.D. Wynne, M.L. Scheinbaum and W.R. Buckett, Effect on radiolabeledmonoamine uptake in vitro of plasma taken from healthyvolunteers administered the antidepressant sibutramine HCl,Psychopharmacology, 100, 345-349 (1990).   DOI
17 S.C. Cheetham, J.A. Viggers, N.A. Slater, D.J. Heal and W.R. Buckett, [$^3H$]Paroxetine binding in rat frontal cortex strongly correlates with [$^3H$]5-HT uptake: effect of administration of various antidepressant treatments, Neuropharmacology, 32, 737-743 (1993).   DOI
18 B.J. Rolls, C.J. Shide, M.L. Thorwart and J.S. Ulbrecht, Sibutramine reduces food intake in nondieting women with obesity. Obes. Res., 6, 1-11 (1998).   DOI   ScienceOn
19 D.L. Hansen, S. Toubro, M.J. Stock, I.A. Macdonald and A. Astrup, Thermogenic effects of sibutramine in humans, Am. J. Clin. Natr., 68, 1180-1186 (1998).   DOI